Seattle, WA, United States
Seattle, WA, United States

Time filter

Source Type

News Article | December 27, 2016
Site: marketersmedia.com

— "Liquid biopsies are a sequencing-based technology used to screen blood for tiny fragments of genetic material released by cancer tissue, known as circulating tumor (ct) DNA. This report mainly covers the Liquid Biopsy Products product type by technology (circulating Tumor Cells (CTCs), circulating tumor DNA (ctDNA), and extracellular vesicles (or exosomes)), by sample type (blood, urine and other bio fluids (Tissue fluids and Saliva based)), while we can also offer any product survey report related to the liquid biopsy products industry chain. " Scope of the Report: This report focuses on the Liquid Biopsy Products in Global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application. For more information or any query mail at sales@wiseguyreports.com Market Segment by Regions, regional analysis covers North America (USA, Canada and Mexico) Europe (Germany, France, UK, Russia and Italy) Asia-Pacific (China, Japan, Korea, India and Southeast Asia) South America, Middle East and Africa Market Segment by Applications, can be divided into Blood Sample Urine Sample Other Bio Fluids There are 13 Chapters to deeply display the global Liquid Biopsy Products market. Chapter 2, to analyze the top manufacturers of Liquid Biopsy Products, with sales, revenue, and price of Liquid Biopsy Products, in 2015 and 2016; Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2015 and 2016; Chapter 4, to show the global market by regions, with sales, revenue and market share of Liquid Biopsy Products, for each region, from 2011 to 2016; 2 Manufacturers Profiles 2.1 RainDance Technologies 2.1.1 Business Overview 2.1.2 Liquid Biopsy Products Type and Applications 2.1.2.1 Type 1 2.1.2.2 Type 2 2.1.3 RainDance Technologies Liquid Biopsy Products Sales, Price, Revenue, Gross Margin and Market Share 2.2 Biocartis 2.2.1 Business Overview 2.2.2 Liquid Biopsy Products Type and Applications 2.2.2.1 Type 1 2.2.2.2 Type 2 2.2.3 Biocartis Liquid Biopsy Products Sales, Price, Revenue, Gross Margin and Market Share 2.3 Qiagen 2.3.1 Business Overview 2.3.2 Liquid Biopsy Products Type and Applications 2.3.2.1 Type 1 2.3.2.2 Type 2 2.3.3 Qiagen Liquid Biopsy Products Sales, Price, Revenue, Gross Margin and Market Share 2.4 Guardant Health 2.4.1 Business Overview 2.4.2 Liquid Biopsy Products Type and Applications 2.4.2.1 Type 1 2.4.2.2 Type 2 2.4.3 Guardant Health Liquid Biopsy Products Sales, Price, Revenue, Gross Margin and Market Share 2.5 MDxHealth 2.5.1 Business Overview 2.5.2 Liquid Biopsy Products Type and Applications 2.5.2.1 Type 1 2.5.2.2 Type 2 2.5.3 MDxHealth Liquid Biopsy Products Sales, Price, Revenue, Gross Margin and Market Share 2.6 Pathway Genomics 2.6.1 Business Overview 2.6.2 Liquid Biopsy Products Type and Applications 2.6.2.1 Type 1 2.6.2.2 Type 2 2.6.3 Pathway Genomics Liquid Biopsy Products Sales, Price, Revenue, Gross Margin and Market Share 2.7 NeoGenomics Laboraories 2.7.1 Business Overview 2.7.2 Liquid Biopsy Products Type and Applications 2.7.2.1 Type 1 2.7.2.2 Type 2 2.7.3 NeoGenomics Laboraories Liquid Biopsy Products Sales, Price, Revenue, Gross Margin and Market Share 2.8 Sysmex Inostics 2.8.1 Business Overview 2.8.2 Liquid Biopsy Products Type and Applications 2.8.2.1 Type 1 2.8.2.2 Type 2 2.8.3 Sysmex Inostics Liquid Biopsy Products Sales, Price, Revenue, Gross Margin and Market Share 2.9 Cynvenio 2.9.1 Business Overview 2.9.2 Liquid Biopsy Products Type and Applications 2.9.2.1 Type 1 2.9.2.2 Type 2 2.9.3 Cynvenio Liquid Biopsy Products Sales, Price, Revenue, Gross Margin and Market Share 2.10 Menarini Silicon Biosystems 2.10.1 Business Overview 2.10.2 Liquid Biopsy Products Type and Applications 2.10.2.1 Type 1 2.10.2.2 Type 2 2.10.3 Menarini Silicon Biosystems Liquid Biopsy Products Sales, Price, Revenue, Gross Margin and Market Share 2.11 Adaptive Biotechnologies 2.11.1 Business Overview 2.11.2 Liquid Biopsy Products Type and Applications 2.11.2.1 Type 1 2.11.2.2 Type 2 2.11.3 Adaptive Biotechnologies Liquid Biopsy Products Sales, Price, Revenue, Gross Margin and Market Share 2.12 Biocept 2.12.1 Business Overview 2.12.2 Liquid Biopsy Products Type and Applications 2.12.2.1 Type 1 2.12.2.2 Type 2 2.12.3 Biocept Liquid Biopsy Products Sales, Price, Revenue, Gross Margin and Market Share 2.13 Angle plc 2.13.1 Business Overview 2.13.2 Liquid Biopsy Products Type and Applications 2.13.2.1 Type 1 2.13.2.2 Type 2 2.13.3 Angle plc Liquid Biopsy Products Sales, Price, Revenue, Gross Margin and Market Share 3 Global Liquid Biopsy Products Market Competition, by Manufacturer 3.1 Global Liquid Biopsy Products Sales and Market Share by Manufacturer 3.2 Global Liquid Biopsy Products Revenue and Market Share by Manufacturer 3.3 Market Concentration Rate 3.3.1 Top 3 Liquid Biopsy Products Manufacturer Market Share 3.3.2 Top 6 Liquid Biopsy Products Manufacturer Market Share 3.4 Market Competition Trend For more information or any query mail at sales@wiseguyreports.com ABOUT US: Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports features an exhaustive list of market research reports from hundreds of publishers worldwide. We boast a database spanning virtually every market category and an even more comprehensive collection of market research reports under these categories and sub-categories. For more information, please visit https://www.wiseguyreports.com


Global Liquid Biopsy market is expected to grow from $0.63 billion in 2015 to reach $2.93 billion by 2022 with a CAGR of 24.6%. Increasing research & developments and clinical trials for diagnostics, and technological developments are some of the factors driving the market growth. Moreover, growing prevalence of cancer, increasing awareness about liquid biopsy are the factors fostering the market growth. On the other hand, higher costs and complex regulations are restraining the market growth. The circulating tumor cells leads the market globally with the biggest market share and is expected to grow with a high CAGR during the forecast period. By cancer type, lung cancer segment is expected to witness high growth rate during the forecast period. North America emerged as the major revenue generating region in the global market due to innovative technological developments, and increasing incidence of cancer rates in the Canada and U.S. Asia Pacific and Latin America are expected to witness high growth rate during the forecast period. Some of the key players in global liquid biopsy market include Adaptive Biotechnologies, Biocept, Inc., Bio-Rad Laboratories Inc., Guardant Health Inc., Fraunhofer-Gesellschaft, F. Hoffmann-La Roche AG, Epic Sciences, Cynvenio, Illumina Inc., Qiagen, Personal Genome Diagnostics, NeoGenomics Laboratories, Myriad Genetics, Trovagene Inc., RainDance Technologies, MDX Health SA, and Janssen Diagnostics, LLC. Regions Covered:  • North America  o US  o Canada  o Mexico  • Europe  o Germany  o France  o Italy  o UK  o Spain  o Rest of Europe  • Asia Pacific  o Japan  o China  o India  o Australia  o New Zealand  o Rest of Asia Pacific  • Rest of the World  o Middle East  o Brazil  o Argentina  o South Africa  o Egypt What our report offers:  - Market share assessments for the regional and country level segments  - Market share analysis of the top industry players  - Strategic recommendations for the new entrants  - Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets  - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)  - Strategic recommendations in key business segments based on the market estimations  - Competitive landscaping mapping the key common trends  - Company profiling with detailed strategies, financials, and recent developments  - Supply chain trends mapping the latest technological About Us Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.


News Article | November 22, 2016
Site: www.newsmaker.com.au

According to Stratistics MRC, the Global Liquid Biopsy market is expected to grow from $0.63 billion in 2015 to reach $2.93 billion by 2022 with a CAGR of 24.6%. Increasing research & developments and clinical trials for diagnostics, and technological developments are some of the factors driving the market growth. Moreover, growing prevalence of cancer, increasing awareness about liquid biopsy are the factors fostering the market growth. On the other hand, higher costs and complex regulations are restraining the market growth. Access the complete report at: The circulating tumor cells leads the market globally with the biggest market share and is expected to grow with a high CAGR during the forecast period. By cancer type, lung cancer segment is expected to witness high growth rate during the forecast period. North America emerged as the major revenue generating region in the global market due to innovative technological developments, and increasing incidence of cancer rates in the Canada and U.S. Asia Pacific and Latin America are expected to witness high growth rate during the forecast period. Some of the key players in global liquid biopsy market include Adaptive Biotechnologies, Biocept, Inc., Bio-Rad Laboratories Inc., Guardant Health Inc., Fraunhofer-Gesellschaft, F. Hoffmann-La Roche AG, Epic Sciences, Cynvenio, Illumina Inc., Qiagen, Personal Genome Diagnostics, NeoGenomics Laboratories, Myriad Genetics, Trovagene Inc., RainDance Technologies, MDX Health SA, and Janssen Diagnostics, LLC.  Request for a sample at: http://www.strategymrc.com/report/liquid-biopsy-market Sample Types Covered: • Urine • Blood • Others o CSF o Plasma o Saliva Cancer Types Covered: • Gastrointestinal Cancer • Colorectal Cancer • Breast Cancer • Leukemia • Prostate Cancer • Lung Cancer • Liver Cancer • Other Cancers o Ovarian Cancer o Melanoma o Bladder Cancer Circulating Biomarkers Covered: • Extracellular Vesicles (EVs) • Circulating Tumor DNA (ctDNA) • Exosomes • Circulating Tumor Cells (CTCs) • Other Biomarkers o Circulating RNA and Protein Products and Services Covered: • Services and Software • Reagents • Instruments End Users Covered: • Hospital and Physician Laboratories • Diagnostic Centers • Academic & Research Centers • Others End User o Small Molecular Laboratories o Public Health Laboratories o Pathology Laboratories Regions Covered: • North America o US o Canada o Mexico • Europe o Germany o France o Italy o UK  o Spain      o Rest of Europe  • Asia Pacific o Japan o China o India o Australia o New Zealand o Rest of Asia Pacific • Rest of the World o Middle East o Brazil o Argentina o South Africa o Egypt What our report offers: - Market share assessments for the regional and country level segments - Market share analysis of the top industry players - Strategic recommendations for the new entrants - Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) - Strategic recommendations in key business segments based on the market estimations - Competitive landscaping mapping the key common trends - Company profiling with detailed strategies, financials, and recent developments - Supply chain trends mapping the latest technological advancements


News Article | November 2, 2016
Site: www.newsmaker.com.au

This report studies sales (consumption) of Liquid Biopsy Products in Global market, especially in United States, China, Europe, Japan, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering RainDance Technologies  Biocartis  Qiagen  Guardant Health  MDxHealth  Pathway Genomics  NeoGenomics Laboraories  Sysmex Inostics  Cynvenio  Silicon Biosystems  Adaptive Biotechnologies  Biocept  Angle plc  ...  Market Segment by Regions, this report splits Global into several key Regions, with sales (consumption), revenue, market share and growth rate of Liquid Biopsy Products in these regions, from 2011 to 2021 (forecast), like  USA  China  Europe  Japan  Split by product Types, with sales, revenue, price and gross margin, market share and growth rate of each type, can be divided into  CTC  ctDNA  Exosomes  Split by applications, this report focuses on sales, market share and growth rate of Liquid Biopsy Products in each application, can be divided into  Blood Sample  Urine Sample  Other Bio Fluids Global Liquid Biopsy Products Sales Market Report 2016  1 Liquid Biopsy Products Overview  1.1 Product Overview and Scope of Liquid Biopsy Products  1.2 Classification of Liquid Biopsy Products  1.2.1 CTC  1.2.2 ctDNA  1.2.3 Exosomes  1.3 Application of Liquid Biopsy Products  1.3.1 Blood Sample  1.3.2 Urine Sample  1.3.3 Other Bio Fluids  1.4 Liquid Biopsy Products Market by Regions  1.4.1 USA Status and Prospect (2011-2021)  1.4.2 China Status and Prospect (2011-2021)  1.4.3 Europe Status and Prospect (2011-2021)  1.4.4 Japan Status and Prospect (2011-2021)  1.5 Global Market Size (Value and Volume) of Liquid Biopsy Products (2011-2021)  1.5.1 Global Liquid Biopsy Products Sales and Growth Rate (2011-2021)  1.5.2 Global Liquid Biopsy Products Revenue and Growth Rate (2011-2021) 2 Global Liquid Biopsy Products Competition by Manufacturers, Type and Application  2.1 Global Liquid Biopsy Products Market Competition by Manufacturers  2.1.1 Global Liquid Biopsy Products Sales and Market Share of Key Manufacturers (2011-2016)  2.1.2 Global Liquid Biopsy Products Revenue and Share by Manufacturers (2011-2016)  2.2 Global Liquid Biopsy Products (Volume and Value) by Type  2.2.1 Global Liquid Biopsy Products Sales and Market Share by Type (2011-2016)  2.2.2 Global Liquid Biopsy Products Revenue and Market Share by Type (2011-2016)  2.3 Global Liquid Biopsy Products (Volume and Value) by Regions  2.3.1 Global Liquid Biopsy Products Sales and Market Share by Regions (2011-2016)  2.3.2 Global Liquid Biopsy Products Revenue and Market Share by Regions (2011-2016)  2.4 Global Liquid Biopsy Products (Volume) by Application GET EXCLUSIVE DISCOUNT ON THIS REPORT @ https://www.wiseguyreports.com/check-discount/721608-global-liquid-biopsy-products-sales-market-report-2016 Figure Picture of Liquid Biopsy Products  Table Classification of Liquid Biopsy Products  Figure Global Sales Market Share of Liquid Biopsy Products by Type in 2015  Figure CTC Picture  Figure ctDNA Picture  Figure Exosomes Picture  Table Applications of Liquid Biopsy Products  Figure Global Sales Market Share of Liquid Biopsy Products by Application in 2015  Figure Blood Sample Examples  Figure Urine Sample Examples  Figure Other Bio Fluids Examples  Figure USA Liquid Biopsy Products Revenue and Growth Rate (2011-2021)  Figure China Liquid Biopsy Products Revenue and Growth Rate (2011-2021)  Figure Europe Liquid Biopsy Products Revenue and Growth Rate (2011-2021)  Figure Japan Liquid Biopsy Products Revenue and Growth Rate (2011-2021)  Figure Global Liquid Biopsy Products Sales and Growth Rate (2011-2021)  Figure Global Liquid Biopsy Products Revenue and Growth Rate (2011-2021)  Table Global Liquid Biopsy Products Sales of Key Manufacturers (2011-2016)  Table Global Liquid Biopsy Products Sales Share by Manufacturers (2011-2016) FOR ANY QUERY, REACH US @ https://www.wiseguyreports.com/enquiry/721608-global-liquid-biopsy-products-sales-market-report-2016


SEATTLE--(BUSINESS WIRE)--Adaptive Biotechnologies, the leader in combining next-generation sequencing (NGS) and expert bioinformatics to profile T- and B-cell receptors of the adaptive immune system, announces that the National Comprehensive Cancer Network (NCCN) revised their clinical practice guidelines recommending the use of highly sensitive diagnostic tools, including NGS, to assess the presence of measurable residual disease (MRD) in Multiple Myeloma. Results from these new innovative cl


News Article | February 24, 2017
Site: www.eurekalert.org

A new discovery by researchers at the Fred Hutchinson Cancer Research Center in Seattle makes an important step in identifying which specific T cells within the diverse army of a person's immune system are best suited to fight cancer. The findings will be published February 24 in Science Immunology. "We found that the cells in each patient's immune system that will ultimately have a clinical effect are incredibly rare," said Dr. Aude Chapuis, lead author of the paper and a member of the Clinical Research Division at Fred Hutch. "Knowing what we've found, we can now refine the selection of the cells that we will ultimately use for adoptive T cell transfer, so that the cells persist and keep the tumors at bay longer in our patients." Dr. Chapuis is an expert in adoptive T cell transfer, a new class of treatments that use immune T cells to fight cancer. It works by obtaining T cells from the patient's own blood, priming them to seek and destroy cancerous cells, multiplying them in the lab and then returning them to the patient. In some treatment settings, the cancer-targeting T cells are instead obtained from a healthy donor's blood. But since each infusion contains thousands of varieties of T cells each with varying cancer-killing capabilities, it's been unclear which ones offer the most effective anti-cancer punch. Making it more complicated, the cells' anti-cancer properties change as they grow in the lab. The offspring or "clones" they create differ from the originals. It's like a "black box," Dr. Chapuis said, in that scientists have rarely been able to identify the composition of cells that are leading the attack on cancer. A newly developed method of tracking cells lets light into that black box. "High throughput T cell receptor sequencing allows us to distinguish the cells and figure out where they came from, which ones grow in culture and which ones persist after being transferred to the patient," said Dr. Chapuis, who is also an assistant professor in the University of Washington's School of Medicine. "We can finally track in detail what's going on when doing adoptive T cell transfers," she said. The method distinguishes T cells from each other according to the nature of their receptor, which is T cells' weapon against cancer. Adaptive Biotechnologies Corp, a spinout of Fred Hutch, developed high-throughput receptor sequencing for immune cells. The technology gives each T cell receptor a "bar code," allowing the researchers to track all of the diverse members of an individual patient's T cell army. Following the bar codes of the T cell receptors, Fred Hutch scientists are tracking thousands of immune cells after being transferred into patients. They then examined how the cells in the mix related to responses to adoptive T cell therapy treatment in 10 metastatic melanoma patients. The researchers found that in the two patients who went into complete remission after T cell infusion, the specific T cells that ended up dominating the patient's cancer-fighting army after infusion were extremely rare in their bodies originally. The method also allowed the researchers to directly observe in humans that the T cells likely having the most powerful effect tended to be younger, suggesting that they had better capabilities to proliferate and survive -- characteristics essential for long-term tumor control. Dr. Chapuis and her collaborators are now looking at how to select out the powerful but rare immune cells and increase their population before being infused into patients. They're testing the approach in two current clinical trials in lung cancer patients (ClinicalTrials.gov identifier NCT02408016) and acute myeloid leukemia patients (NCT02770820). The Cancer Research Institute and Stand Up To Cancer program funded the research. The Fred Hutchinson Cancer Research Center has licensed technology to Adaptive Biotechnologies Corp and owns a stake in the company. In addition to Dr. Chapuis, the other corresponding author of the paper is Cassian Yee, who did the work while at Fred Hutch and is now at the MD Anderson Cancer Center. Other co-authors are Cindy Desmarais, Ryan Emerson, Thomas Schmitt, Kendall Shibuya, Ivy Lai, Felecia Wagener, Jeffrey Chou, Ilana Roberts, David Coffey, Edus Warren, Harlan Robins and Philip Greenberg. Learn more about Dr. Chapuis' research in a video: https:/ At Fred Hutchinson Cancer Research Center, home to three Nobel laureates, interdisciplinary teams of world-renowned scientists seek new and innovative ways to prevent, diagnose and treat cancer, HIV/AIDS and other life-threatening diseases. Fred Hutch's pioneering work in bone marrow transplantation led to the development of immunotherapy, which harnesses the power of the immune system to treat cancer. An independent, nonprofit research institute based in Seattle, Fred Hutch houses the nation's first cancer prevention research program, as well as the clinical coordinating center of the Women's Health Initiative and the international headquarters of the HIV Vaccine Trials Network. Private contributions are essential for enabling Fred Hutch scientists to explore novel research opportunities that lead to important medical breakthroughs. For more information visit fredhutch.org or follow Fred Hutch on Facebook, Twitter or YouTube.


News Article | February 27, 2017
Site: www.medicalnewstoday.com

The study - published in the journal Science Immunology - is the work of a team led by researchers at the Fred Hutchinson Cancer Research Center (Fred Hutch) in Seattle, WA. Immunotherapy is an exciting new field in the fight against cancer that uses cells from the patient's own immune system to tackle the disease. However, as in all new medical approaches, it faces immense challenges. From a theoretical standpoint, the idea of using T cells to fight cancer has long been of interest. T cells are members of the adaptive immune system, possessing several features that make them amenable for cancer treatment. For example, T cells react specifically to threats, replicate rapidly, and travel to distant target sites. They also have long memories, suggesting that they can maintain a therapeutic effect for many years after initial treatment. However, while the idea of using T cells looked promising in theory, scientists now face a number of hurdles before turning it into practice. One such challenge - the focus of the new study - is how to identify a readily accessible pool of tumor-specific T cells. The idea of adoptive T cell transfer is to take T cells from the patient's own blood, prime them to target and kill cancer cells, multiply them in the laboratory, and then return them to the patient. In some specific settings, the T cells can come from a healthy donor instead. However, there are thousands of types of T cell - each with a specific cancer-killing effect - and it has not been clear which ones are the most effective against cancer cells. Furthermore, the challenge is heightened by the fact that the cells' anti-cancer effect change as they multiply in the laboratory; the cloned offspring are different to their parents. Lead author Dr. Aude Chapuis, an immunotherapy researcher at Fred Hutch and an expert in adoptive T cell transfer, says: "We found that the cells in each patient's immune system that will ultimately have a clinical effect are incredibly rare." Dr. Chapuis says that trying to identify which cells are leading the attack on the tumor has been like trying to see into a "black box." However, she and her team have discovered a method based on "high throughput T cell receptor sequencing" that sheds light on the problem. Different types of T cell have slightly different weapons for tackling cancer cells, and these weapons can be distinguished by the type of receptor on the T cell. Adaptive Biotechnologies Corp - a spin-off from Fred Hutch - have developed a way of giving each type of T cell receptor a unique "barcode" so that the researchers can read and track all the types of receptor in an individual patient's army of T cells. Dr. Chapuis says that with the new tracking method, they can finally follow in detail what is happening in an individual patient's adoptive T cell transfer. The method allows them to "distinguish the cells and figure out where they came from, which ones grow in culture and which ones persist after being transferred to the patient," she explains. In their study, the researchers used the barcode method to track thousands of immune cells following their transfer into patients. The team assessed how well 10 patients with metastatic melanoma - a disease in which skin cancer had spread to other parts of the body - responded to adoptive T cell therapy using different mixes of T cell types. Two of the patients demonstrated complete remission. On further examination, the team found that in those cases, the T cells that led the fight against the metastatic cancer were types that were extremely rare in the patients' bodies originally. The researchers also used the new tracking method to directly monitor the T cells in the body. They found that the T cells that delivered the strongest anti-cancer punch tended to be younger, suggesting the effect came from the fact that younger cells are more able to replicate and survive - features likely to be important for sustaining long-term effects. The team is now conducting two clinical trials to test how to better extract the rare but powerful T cells and multiply them before returning them to patients. One trial is recruiting lung cancer patients, and the other is recruiting patients with acute myeloid leukemia. In the following video, Dr. Chapuis explains how adoptive T cell transfer fights cancer, the main challenges facing researchers developing this type of immunotherapy, and the progress of the team at Fred Hutch. Learn how immunotherapy may overcome chemotherapy resistance in ovarian cancer.


A new discovery by researchers at the Fred Hutchinson Cancer Research Center in Seattle makes an important step in identifying which specific T cells within the diverse army of a person's immune system are best suited to fight cancer. The findings will be published February 24 in Science Immunology. "We found that the cells in each patient's immune system that will ultimately have a clinical effect are incredibly rare," said Dr. Aude Chapuis, lead author of the paper and a member of the Clinical Research Division at Fred Hutch. "Knowing what we've found, we can now refine the selection of the cells that we will ultimately use for adoptive T cell transfer, so that the cells persist and keep the tumors at bay longer in our patients." Dr. Chapuis is an expert in adoptive T cell transfer, a new class of treatments that use immune T cells to fight cancer. It works by obtaining T cells from the patient's own blood, priming them to seek and destroy cancerous cells, multiplying them in the lab and then returning them to the patient. In some treatment settings, the cancer-targeting T cells are instead obtained from a healthy donor's blood. But since each infusion contains thousands of varieties of T cells each with varying cancer-killing capabilities, it's been unclear which ones offer the most effective anti-cancer punch. Making it more complicated, the cells' anti-cancer properties change as they grow in the lab. The offspring or "clones" they create differ from the originals. It's like a "black box," Dr. Chapuis said, in that scientists have rarely been able to identify the composition of cells that are leading the attack on cancer. A newly developed method of tracking cells lets light into that black box. "High throughput T cell receptor sequencing allows us to distinguish the cells and figure out where they came from, which ones grow in culture and which ones persist after being transferred to the patient," said Dr. Chapuis, who is also an assistant professor in the University of Washington's School of Medicine. "We can finally track in detail what's going on when doing adoptive T cell transfers," she said. The method distinguishes T cells from each other according to the nature of their receptor, which is T cells' weapon against cancer. Adaptive Biotechnologies Corp, a spinout of Fred Hutch, developed high-throughput receptor sequencing for immune cells. The technology gives each T cell receptor a "bar code," allowing the researchers to track all of the diverse members of an individual patient's T cell army. Following the bar codes of the T cell receptors, Fred Hutch scientists are tracking thousands of immune cells after being transferred into patients. They then examined how the cells in the mix related to responses to adoptive T cell therapy treatment in 10 metastatic melanoma patients. The researchers found that in the two patients who went into complete remission after T cell infusion, the specific T cells that ended up dominating the patient's cancer-fighting army after infusion were extremely rare in their bodies originally. The method also allowed the researchers to directly observe in humans that the T cells likely having the most powerful effect tended to be younger, suggesting that they had better capabilities to proliferate and survive -- characteristics essential for long-term tumor control. Dr. Chapuis and her collaborators are now looking at how to select out the powerful but rare immune cells and increase their population before being infused into patients. They're testing the approach in two current clinical trials in lung cancer patients (ClinicalTrials.gov identifier NCT02408016) and acute myeloid leukemia patients (NCT02770820). The Cancer Research Institute and Stand Up To Cancer program funded the research. The Fred Hutchinson Cancer Research Center has licensed technology to Adaptive Biotechnologies Corp and owns a stake in the company. In addition to Dr. Chapuis, the other corresponding author of the paper is Cassian Yee, who did the work while at Fred Hutch and is now at the MD Anderson Cancer Center. Other co-authors are Cindy Desmarais, Ryan Emerson, Thomas Schmitt, Kendall Shibuya, Ivy Lai, Felecia Wagener, Jeffrey Chou, Ilana Roberts, David Coffey, Edus Warren, Harlan Robins and Philip Greenberg.


News Article | November 16, 2016
Site: globenewswire.com

VANCOUVER, Wash., Nov. 16, 2016 (GLOBE NEWSWIRE) -- DiscoverOrg, the leading sales and marketing intelligence provider, announced today that it has earned consecutive honors on Deloitte’s Technology Fast 500™, a ranking of the fastest growing technology, media, telecommunications, life sciences, and energy tech companies in North America. Consistently recognized as the most accurate sales and marketing intelligence provider in the nation, DiscoverOrg grew 274 percent organically during this period. “Making Deloitte’s Technology Fast 500 list for two years running is an incredible honor. It is a testament to the fact that our solution addresses a significant challenge for sales and marketing departments today: finding highly accurate, verified, and actionable data to accelerate revenue growth,” said Henry Schuck, CEO of DiscoverOrg. DiscoverOrg ranked 269th overall, 11th in the state of Washington, and 7th in the Portland metropolitan area. Other leaders in the state include 2nd Watch, Adaptive Biotechnologies, and Flowplay. Among other sales and marketing intelligence providers, DiscoverOrg was the #1 fastest growing, ranking 156 spots higher on the list than any other intelligence vendor included. “Our personal and professional lives are shifting in response to new technologies and business models that are changing the way we work and live,” said Sandra Shirai, principal, Deloitte Consulting LLP and US Technology, Media, and Telecommunications leader. “The 2016 Technology Fast 500 winners are supporting this shift by creating experiences for their customers, surpassing expected possibilities, and helping to envision even more effective and ingenious solutions.” This announcement is the latest in a recent string of national growth awards that the company has earned, including inclusion on the Inc. 5000 for the sixth straight year and the Puget Sound Business Journal’s Fast 100. To learn more about DiscoverOrg, please visit the company’s website (www.discoverorg.com) DiscoverOrg is the leading global sales and marketing intelligence tool used by over 2,000 of the world’s fastest growing companies to accelerate growth. The company itself has been named an Inc. 5000 fastest-growing company six times. DiscoverOrg’s award-winning solutions provide a constant stream of accurate and actionable company, contact, and buying intelligence that can be used to find, connect with, and sell to target buyers more effectively – all integrated into the leading CRM and Marketing Automation Tools in the market. DiscoverOrg’s team of over 250 researchers refreshes every data point at minimum every 60 days – ensuring customers reach the right buyers with the right message at the right time. The Deloitte Technology Fast 500 is the leading technology awards program in North America (United States and Canada). Combining technological innovation, entrepreneurship, and rapid growth, Fast 500 companies — large, small, public, and private — span a variety of industry sectors and are leaders in hardware, software, telecom, semiconductors, life sciences, and energy tech. These companies are on the cutting edge and are transforming the way we do business today. The Technology Fast 500 provides a ranking of the fastest growing technology, media, telecommunications, life sciences, and energy tech companies in North America. This ranking is compiled from applications submitted directly to the Technology Fast 500 website and public company database research conducted by Deloitte Services LP. Technology Fast 500 award winners for 2016 are determined based on percentage fiscal year revenue growth during the period from 2012 to 2015. The ranking includes both public and private companies.


SEATTLE--(BUSINESS WIRE)--Adaptive Biotechnologies, the leader in combining next-generation sequencing (NGS) and expert bioinformatics to profile T- and B-cell receptors of the adaptive immune system, and its collaborators from pharmaceutical companies and academic centers around the world, will share data further demonstrating the clinical validity and prognostic value of the clonoSEQ Assay for MRD assessment in lymphoid cancers. Data including MRD assessment and T-cell repertoire characteriza

Loading Adaptive Biotechnologies collaborators
Loading Adaptive Biotechnologies collaborators